Adam H. Golden
Head of the Corporate Practice Group in New York, Adam Golden advises life sciences companies on their most important transactions. Clients turn to Adam for his dual skillset, which combines his strengths as an M&A and corporate lawyer, with those of an IP transactions lawyer. This enables him to represent pharmaceutical, biotech, and medical device companies in the full scope of transactions that are common to this sector.
Over his career, Adam has advised clients on M&A, capital markets transactions, license and collaboration deals, venture capital financings, and commercial transactions. Frequently, clients seek his advice on hybrid transactions such as M&A transactions with back-end milestone payments, options to acquire companies or technology, and product divestitures. He also advises clients on the transition service, manufacturing and supply, and other operational agreements that often accompany these transactions.
Adam is recognized as a leading practitioner in Chambers Global, Chambers USA, Legal 500 US, Who's Who Legal, LMG Life Sciences, and IAM Patent 1000.
"M&A and licensing for the likes of Pfizer and Novartis is all in a day's work for this life sciences star."
"Adam Golden is an M&A and licensing expert who regularly represents clients in both acquisitions and divestments of multi-billion dollar business units."
Advised Novartis in the acquisition of GSK's oncology business for up to US$16bn.
Advised Allergan in the acquisition of rights to Ironwood Pharmaceuticals' linaclotide product (CONSTELLA®) in more than 40 countries outside the U.S.
Counseled Sandoz in the acquisition of Fougera Pharmaceuticals for approximately US$1.5bn.
Helped Celgene in R&D collaborations and options to acquire research-stage biotech companies.
Assisted Pfizer in the acquisition of NextWave Pharmaceuticals for up to US$700m.
Counseled principal stockholder of iMDsoft in its sale to TPG Capital.
Guided Vatera Healthcare in venture capital investments in biopharmaceutical companies.
Aided Novartis in exclusive global collaboration agreement with the University of Pennsylvania to develop and commercialize immunotherapies for cancer.
Nationwide, Life Sciences: Corporate/Commercial
Global-wide, Life Sciences: Corporate/Commercial
Life Sciences - Transactional
Who's Who Legal
The World's Leading Patent Practitioners
IAM Patent 1000
Life Sciences Star - Finance & Transactional
LMG Life Sciences
Healthcare: Life Sciences
Legal 500 US
Leading Lawyers for Business